Merck, known as MSD outside of the United States and Canada, announced that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (Blackstone) for the ...

Lepu Biopharma Co. Ltd. said Oct. 30 it won Chinese approval of a novel antibody-drug conjugate (ADC), Meiyouheng (becotatug ...

This data is encouraging as it reinforces the large and growing body of evidence indicating that certepetide can enhance the targeting, penetration, and effectiveness of therapeutic agents - in this ...

Simtra BioPharma Solutions is advancing a dual-continent expansion aimed at boosting capacity for sterile injectable drugs.

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

Merck is currently evaluating Sac-TMT in 15 global late-stage trials spanning six tumor types, including breast, endometrial, and lung cancers. ・Separately, the company also said that it has now ...

The deadline for required immunizations for Muscogee County School District is technically July 31, but schools allow a ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Merck (MRK) stock is in focus as the company secures $700M from Blackstone to advance cancer therapy sacituzumab tirumotecan ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences ...

(“Sintana ”) and Challenger Energy Group plc (“Challenger ”) earlier today, we have reached another milestone associated with our proposed all-share acquisition of Challenger. A Scheme Document in ...

Based on strong preclinical data on HMPL-A251 in HER2-positive tumor cell lines, the firm wants to take the therapy into clinical trials by year end.